Triple Immune Regimen for HIV
Trial Summary
The research on enfuvirtide, a drug used in combination with other antiretrovirals, shows that it can significantly increase CD4+ cell counts and reduce HIV RNA levels, suggesting potential benefits for immune system improvement in HIV patients.
2691014The trial does not specify if you need to stop your current medications, but you must be on a specific HIV treatment regimen before joining. You cannot use complementary or alternative medicines within 14 days before starting the study.
The Triple Immune Regimen for HIV is unique because it combines multiple components, including ChAdOx1 and MVA vectors, which are designed to stimulate the immune system in a novel way, potentially offering a different mechanism of action compared to traditional antiretroviral therapies that primarily target viral replication.
12348Eligibility Criteria
Adults who started ART for acute HIV within 28 days of diagnosis, have been on consistent treatment without breaks longer than 14 days, and have maintained an undetectable viral load for at least a year. They must weigh between 50-115 kg, have a CD4 count ≥500 cells/mm3, and agree to use two forms of contraception if applicable.Inclusion Criteria
Exclusion Criteria